Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults

Li, C; Liu, HY; Liao, YX; Zhu, Y; Tian, JY; Wang, X; Hu, ZQ; Zhan, YX; Li, XB; Liang, XT; He, J; Li, YM; Shang, DW; Zheng, QS; Wang, TH; Song, HF; Fang, Y

Wang, TH (通讯作者)，Guangzhou Med Univ, Dept Pharm, Key Lab Biol Targeting Diag Therapy & Rehabil Guan, Affiliated Hosp 5, Guangzhou, Peoples R China.;Song, HF (通讯作者)，Beijing Inst Radiat Med, Dept Pharmacol & Toxicol, Beijing, Peoples R China.;Fang, Y (通讯作者)，Peking Univ Peoples Hosp, Clin Trial Inst Res Ward, Beijing, Peoples R China.

BIODRUGS, 2023; 37 (5): 721

Abstract

BackgroundGB223 is a novel, fully-humanized monoclonal antibody against the receptor activator of nuclear factor-kappa B ligand (RANKL). In this phase......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索